{"protocolSection": {"identificationModule": {"nctId": "NCT01454284", "orgStudyIdInfo": {"id": "12147"}, "secondaryIdInfos": [{"id": "I2R-MC-BIAO", "type": "OTHER", "domain": "Eli Lilly and Company"}, {"id": "2011-001253-82", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Eli Lilly and Company", "class": "INDUSTRY"}, "briefTitle": "A Study in Participants With Type I Diabetes Mellitus", "officialTitle": "The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: a Double-Blind, Randomized, 52-week Study", "acronym": "IMAGINE 3"}, "statusModule": {"statusVerifiedDate": "2018-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-01"}, "primaryCompletionDateStruct": {"date": "2014-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-10-14", "studyFirstSubmitQcDate": "2011-10-14", "studyFirstPostDateStruct": {"date": "2011-10-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-03-16", "resultsFirstSubmitQcDate": "2018-03-16", "resultsFirstPostDateStruct": {"date": "2018-04-17", "type": "ACTUAL"}, "dispFirstSubmitDate": "2014-04-14", "dispFirstSubmitQcDate": "2014-04-14", "dispFirstPostDateStruct": {"date": "2014-05-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-03-16", "lastUpdatePostDateStruct": {"date": "2018-04-17", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Eli Lilly and Company", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is:\n\n* To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment.\n* To compare the rate of nocturnal low blood sugar episodes on LY2605541 with insulin glargine during 52 weeks of treatment.\n* To compare the number of participants on LY2605541 reaching blood sugar targets without low blood sugar episodes at night to those taking insulin glargine after 52 weeks of treatment.\n* To compare the rate of low blood sugar episodes on LY2605541 with insulin glargine during 52 weeks of treatment"}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 1"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1114, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LY2605541 + Insulin Lispro", "type": "EXPERIMENTAL", "description": "LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC) once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered SC at meal times for 52 weeks.", "interventionNames": ["Drug: LY2605541", "Drug: Insulin Lispro"]}, {"label": "Glargine + Insulin Lispro", "type": "ACTIVE_COMPARATOR", "description": "Glargine dose titrated based on blood glucose readings, administered SC once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered SC at meal times for 52 weeks.", "interventionNames": ["Drug: Glargine", "Drug: Insulin Lispro"]}], "interventions": [{"type": "DRUG", "name": "Glargine", "armGroupLabels": ["Glargine + Insulin Lispro"]}, {"type": "DRUG", "name": "LY2605541", "armGroupLabels": ["LY2605541 + Insulin Lispro"]}, {"type": "DRUG", "name": "Insulin Lispro", "armGroupLabels": ["Glargine + Insulin Lispro", "LY2605541 + Insulin Lispro"], "otherNames": ["LY275585", "Humalog"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Hemoglobin A1c (HbA1c)", "description": "HbA1c is a test that measures a participant's average blood glucose level over a 2 to 3 month timeframe. Least squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, stratification factors (country, baseline low density lipoprotein cholesterol \\[LDL-C\\] \\[\\<100 milligrams/deciliter (mg/dL) (2.6 millimoles/liter \\[mmol/L\\]) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects and participant as the random effect.", "timeFrame": "52 weeks"}], "secondaryOutcomes": [{"measure": "Hemoglobin A1c (HbA1c)", "description": "HbA1c is a test that measures a participant's average blood glucose level over the past 2 to 3 months. LS means were calculated using MMRM adjusting for treatment, stratification factors (country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects and participant as the random effect.", "timeFrame": "26 weeks"}, {"measure": "Change From Baseline to 52 Weeks in HbA1c", "description": "HbA1c is a test that measures a participant's average blood glucose level over a 2 to 3 month timeframe. LS means were calculated using MMRM adjusting for treatment, stratification factors (country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects and participant as the random effect.", "timeFrame": "Baseline, 52 weeks"}, {"measure": "Total Hypoglycemia Events", "description": "Hypoglycemic episodes are defined as events which are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of \u226470 mg/dL (3.9 mmol/L). Group mean rates of total hypoglycemia (per 30 days) are presented and were calculated from negative binomial regression models (number of episodes = treatment + baseline total hypoglycemia rate, with log \\[exposure in days/30\\] as an offset variable). Group mean is estimated by taking the inverse link function on individual participant covariates first and then averages over all participants.", "timeFrame": "Baseline through 26 weeks, Baseline through 52 weeks"}, {"measure": "Percentage of Participants With Total Hypoglycemic Events", "description": "Hypoglycemic episodes are defined as events that are associated with the reported signs and symptoms of hypoglycemia and/or documented BG concentrations of \u226470 mg/dL (3.9 mmol/L). The percentage of participants was calculated by dividing the number of participants with hypoglycemic episodes by the total number of participants analyzed, multiplied by 100.", "timeFrame": "Baseline through 26 weeks, Baseline through 52 weeks"}, {"measure": "Percentage of Participants With HbA1c Equal to or Less Than 6.5% and Less Than 7.0%", "description": "The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.", "timeFrame": "up to 26 weeks, up to 52 weeks"}, {"measure": "Percentage of Participants With HbA1c Less Than 7.0% and Without Nocturnal Hypoglycemia", "description": "Hypoglycemic episodes are defined as events associated with reported signs and symptoms of hypoglycemia and/or a documented blood glucose concentration of \u226470 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. The percentage of participants was calculated by dividing the number of participants with HbA1c \\<7.0% without nocturnal hypoglycemia by the total number of participants analyzed, multiplied by 100.", "timeFrame": "up to 26 weeks, up to 52 weeks"}, {"measure": "Nocturnal Hypoglycemia Rates", "description": "Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or a documented BG concentration of \u226470 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. Group mean rates of nocturnal hypoglycemia (per 30 days) are presented and were calculated from negative binomial regression models (number of episodes = treatment + baseline nocturnal hypoglycemia rate, with log \\[exposure in days/30\\] as an offset variable). Group mean is estimated by taking the inverse link function on individual participant covariates first and then averages over all participants.", "timeFrame": "Baseline through 26 weeks, Baseline through 52 weeks"}, {"measure": "Percentage of Participants With Nocturnal Hypoglycemic Events", "description": "Hypoglycemic episodes are defined as events associated with the reported signs and symptoms of hypoglycemia and/or a BG concentration of \u226470 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. The percentage of participants was calculated by dividing the number of participants with nocturnal hypoglycemic episodes by the total number of participants analyzed, multiplied by 100.", "timeFrame": "Baseline through 26 weeks, Baseline through 52 weeks"}, {"measure": "Change in Body Weight", "description": "LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline body weight as fixed effects and participant as the random effect.", "timeFrame": "Baseline, 26 weeks, 52 weeks"}, {"measure": "9 Point Self-monitored Blood Glucose (SMBG)", "description": "9-point SMBG profiles were obtained over 2 days within the week prior to Weeks 0, 4, 12, 26, 39, and 52. SMBG measurements were taken at 9 time points: pre-morning meal, 2 hours post-morning meal, pre-midday meal, 2 hours post-midday meal, pre-evening meal, 2 hours post-evening meal, bedtime, at approximately 0300 hours, and the subsequent morning prior to the morning meal. LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline BG values as the fixed effects and participant as the random effect.", "timeFrame": "26 weeks and 52 weeks"}, {"measure": "Fasting Serum Glucose (by Laboratory Measurement)", "description": "Fasting serum glucose (FSG) is measured in blood before the morning meal. LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects and participant as the random effect.", "timeFrame": "26 weeks and 52 weeks"}, {"measure": "Fasting Blood Glucose (by Participant Self Monitored Blood Glucose Readings)", "description": "Fasting blood glucose (FBG) was measured by SMBG pre-morning meal. LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline FBG as the fixed effects and participant as the random effect.", "timeFrame": "26 weeks and 52 weeks"}, {"measure": "Intra-participant Variability of Fasting Blood Glucose (FBG)", "description": "FBG was measured by SMBG. Between-day glucose variability is measured by the standard deviation (SD) of FBG. LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline SD of FBG as the fixed effects and participant as the random effect.", "timeFrame": "26 weeks and 52 weeks"}, {"measure": "0300 Hours Blood Glucose (BG) to Fasting BG Excursion", "description": "Results of a 0300-hour to pre-morning meal (FBG) excursion are presented (only excursions within a single SMBG profile are included). LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline excursion as the fixed effects and participant as the random effect.", "timeFrame": "26 weeks and 52 weeks"}, {"measure": "Triglycerides, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C), and Total Cholesterol", "description": "Concentrations of cholesterol, HDL-C, and LDL-C, and triglycerides are presented. LS means were calculated using MMRM adjusting for stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L), except for the LDL-C outcome variable\\], prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment, treatment-by-visit interaction, and baseline value of corresponding lipid outcome variable as the fixed effects and participant as a random effect.", "timeFrame": "26 weeks and 52 weeks"}, {"measure": "Percentage of Participants With Change in Anti-LY2605541 Antibodies", "description": "The percentage of participants with anti-LY2605541 treatment-emergent antibody response (TEAR) is summarized. TEAR is defined as change from baseline to post-baseline in the anti-LY2605541 antibody level either from undetectable to detectable, or from detectable to the value with at least 130% relative increase from baseline.", "timeFrame": "26 weeks, 52 weeks"}, {"measure": "Basal, Meal Time, and Total Insulin Dose Per Body Weight", "description": "Basal insulin dose, meal-time insulin dose (short-acting bolus dose), and total insulin dose were calculated based on the dose during the last 7 days prior to the post-treatment visit or last 3 days prior to the randomization visit. LS means were calculated using a constrained Longitudinal Data Analysis (cLDA) model adjusting for indicator variables of each treatment group at each postbaseline visit and stratification variables (baseline HbA1c \\[\u22648.5% and\\> 8.5%\\], country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], and baseline prior basal insulin therapy \\[insulin glargine/detemir/ other\\]) as fixed effects.", "timeFrame": "26 weeks and 52 weeks"}, {"measure": "Insulin Treatment Satisfaction Questionnaire", "description": "Insulin Treatment Satisfaction Questionnaire (ITSQ) is a validated measure containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Convenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, and Insulin Delivery Device. Data are transformed to a scale of 0-100, where higher scores indicate better treatment satisfaction. LS means were calculated using an ANCOVA model adjusting for treatment, baseline HbA1c (\u22648.5% and \\>8.5%), country, and baseline prior basal insulin therapy (insulin glargine/detemir/other) as fixed effects and baseline ITSQ scores as a covariate.", "timeFrame": "up to 52 weeks"}, {"measure": "European Quality of Life -5 Dimension (EQ-5D-3L)", "description": "The EQ-5D-3L is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a three-level scale of 1-3 (no problem, some problems, and extreme problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United States population-based algorithm. Scores range from -0.11 to 1.0, where a score of 1.0 indicates perfect health. LS means were calculated using an ANCOVA adjusting for treatment, baseline HbA1c (\u22648.5% and \\>8.5%), country, baseline prior basal insulin therapy (insulin glargine/detemir/other), and baseline EQ-5D-3L score as covariates.", "timeFrame": "up to 52 weeks"}, {"measure": "Adult Low Blood Sugar Survey", "description": "Low Blood Sugar Survey (LBSS) (also referenced as Hypoglycemia Fear Survey - II \\[HFS-II\\]) is a questionnaire that measures 1) behaviors to avoid hypoglycemia and its negative consequences (15 items) and 2) worries about hypoglycemia and its negative consequences (18 items). Responses are made on a 5-point Likert-type scale where 0 = Never and 4 = Always. Total score is the sum of all items (range 0-132). Higher total scores reflect greater fear of hypoglycemia. LS means were calculated using MMRM adjusting for treatment, baseline HbA1c (\u22648.5% and \\>8.5%), country, baseline prior basal insulin therapy (insulin glargine/detemir/other), visit, treatment-by-visit interaction, and baseline LBSS score as the fixed effects and participant as the random effect.", "timeFrame": "26 weeks and 52 weeks"}, {"measure": "Rapid Assessment of Physical Activity (RAPA)", "description": "The RAPA questionnaire assesses the level and intensity of physical activity of adult participants. It contains 2 subscales: RAPA 1 (Aerobic) and RAPA 2 (Strength and Flexibility). RAPA 1 contains 7 questions regarding the participant's amount and intensity of physical activity, allowing each participant's aerobic activity level to be categorized as sedentary, underactive, light activity, regular underactive, or active. RAPA 2 contains 2 questions regarding participants' physical activities that increase strength and improve flexibility. Each participant's strength and flexibility activity level is then categorized as neither strength nor flexibility activity, either strength or flexibility activity (not both), both strength and flexibility activity. The percentage of participants in each RAPA 1/2 category is presented and was calculated by dividing the number of participants in each RAPA 1/2 category by the total number of participants analyzed, multiplied by 100.", "timeFrame": "52 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 1 diabetes for at least 1 year\n* HbA1c value less than 12 percent according to the central laboratory at screening\n* Body mass index of less than or equal to 35.0 kilograms per square meter (kg/m\\^2)\n* Have been treated for at least 90 days prior to screening with\n\n  * insulin detemir, insulin glargine, or Neutral Protamine Hagedorn (NPH) in combination with pre-meal insulin, or\n  * self-mixed or pre-mixed insulin regimens with any basal and bolus insulin combination administered at least twice daily, or\n  * continuous SC insulin infusion therapy\n* Women who are not breast feeding and test negative for pregnancy before receiving treatment and agree to use reliable birth control until 2 weeks after last treatment with study drug\n* Are capable and willing to adhere to multiple daily injections, inject with a vial and syringe and prefilled pen and perform self-monitored blood glucose (SMBG) readings and record keeping\n\nExclusion Criteria:\n\n* Are using twice daily insulin glargine having been inadequately controlled on single daily dose of glargine prior to screening\n* Excessive insulin resistance defined as having received a total daily dose of insulin greater than 1.5 units per kilogram (U/kg) at the time of randomization\n* Receiving any oral or injectable medication (other than insulins or metformin for treatment of polycystic ovarian disease) intended for the treatment of diabetes mellitus in the 90 days prior to screening\n* Lipid lowering medications:\n\n  * are using niacin preparations as lipid lowering medication and/or bile acid sequestrants within 90 days prior to screening; or,\n  * are using lipid lowering medication at a dose that has not been stable for 90 days or more prior to screening\n* Have fasting hypertriglyceridemia (defined as greater than 4.5 millimoles per liter \\[mmol/L\\], greater than 400 milligrams per deciliter \\[mg/dL\\]) at screening, as determined by the central laboratory.\n* Have had more than 1 episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) within 6 months prior to screening\n* Have had 2 or more emergency room visits or hospitalizations due to poor glucose control within 6 months prior to screening\n* Have cardiac disease with functional status that is New York Heart Association Class III or IV\n* Have a history of renal transplantation or are currently receiving renal dialysis or have serum creatinine greater than 2.5 mg/dL\n* Have obvious clinical signs or symptoms of liver disease (excluding non-alcoholic fatty liver disease \\[NAFLD\\]), acute or chronic hepatitis, non-alcoholic steatohepatitis (NASH), or elevated liver enzyme measurements as indicated below:\n\n  * total bilirubin 2 times or more than the upper limit of normal (ULN) as defined by the central laboratory, or\n  * alanine aminotransferase (ALT)/(serum glutamic pyruvic transaminase (SGPT) more than 2.5 times ULN as defined by the central laboratory, or\n  * aspartate aminotransferase (AST)/(serum glutamic oxaloacetic transaminase (SGOT) more than 2.5 times ULN as defined by the central laboratory\n* Have active or untreated malignancy, have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer) for less than 5 years, or are at increased risk for developing cancer or a recurrence of cancer\n* Diagnosed clinically significant diabetic autonomic neuropathy", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", "affiliation": "Eli Lilly and Company", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Concord", "state": "California", "zip": "94520", "country": "United States", "geoPoint": {"lat": 37.97798, "lon": -122.03107}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "La Mesa", "state": "California", "zip": "91942", "country": "United States", "geoPoint": {"lat": 32.76783, "lon": -117.02308}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Lancaster", "state": "California", "zip": "93534", "country": "United States", "geoPoint": {"lat": 34.69804, "lon": -118.13674}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Tustin", "state": "California", "zip": "92780", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Aurora", "state": "Colorado", "zip": "80045", "country": "United States", "geoPoint": {"lat": 39.72943, "lon": -104.83192}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Longmont", "state": "Colorado", "zip": "80501", "country": "United States", "geoPoint": {"lat": 40.16721, "lon": -105.10193}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Bradenton", "state": "Florida", "zip": "34208", "country": "United States", "geoPoint": {"lat": 27.49893, "lon": -82.57482}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Hollywood", "state": "Florida", "zip": "33021", "country": "United States", "geoPoint": {"lat": 26.0112, "lon": -80.14949}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Jacksonville", "state": "Florida", "zip": "32258", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "New Port Richey", "state": "Florida", "zip": "34652", "country": "United States", "geoPoint": {"lat": 28.24418, "lon": -82.71927}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "West Palm Beach", "state": "Florida", "zip": "33401", "country": "United States", "geoPoint": {"lat": 26.71534, "lon": -80.05337}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Roswell", "state": "Georgia", "zip": "30076", "country": "United States", "geoPoint": {"lat": 34.02316, "lon": -84.36159}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Honolulu", "state": "Hawaii", "zip": "96814", "country": "United States", "geoPoint": {"lat": 21.30694, "lon": -157.85833}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Idaho Falls", "state": "Idaho", "zip": "83404", "country": "United States", "geoPoint": {"lat": 43.46658, "lon": -112.03414}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Springfield", "state": "Illinois", "zip": "62704", "country": "United States", "geoPoint": {"lat": 39.80172, "lon": -89.64371}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Des Moines", "state": "Iowa", "zip": "50314", "country": "United States", "geoPoint": {"lat": 41.60054, "lon": -93.60911}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Topeka", "state": "Kansas", "zip": "66606", "country": "United States", "geoPoint": {"lat": 39.04833, "lon": -95.67804}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Wichita", "state": "Kansas", "zip": "67226", "country": "United States", "geoPoint": {"lat": 37.69224, "lon": -97.33754}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Lexington", "state": "Kentucky", "zip": "40503", "country": "United States", "geoPoint": {"lat": 37.98869, "lon": -84.47772}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Metairie", "state": "Louisiana", "zip": "70006", "country": "United States", "geoPoint": {"lat": 29.98409, "lon": -90.15285}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Baltimore", "state": "Maryland", "zip": "21204", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Eagan", "state": "Minnesota", "zip": "55123", "country": "United States", "geoPoint": {"lat": 44.80413, "lon": -93.16689}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Minneapolis", "state": "Minnesota", "zip": "55416", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Chesterfield", "state": "Missouri", "zip": "63017", "country": "United States", "geoPoint": {"lat": 38.66311, "lon": -90.57707}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Springfield", "state": "Missouri", "zip": "65807", "country": "United States", "geoPoint": {"lat": 37.21533, "lon": -93.29824}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Billings", "state": "Montana", "zip": "59101", "country": "United States", "geoPoint": {"lat": 45.78329, "lon": -108.50069}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Omaha", "state": "Nebraska", "zip": "68114", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Las Vegas", "state": "Nevada", "zip": "89148", "country": "United States", "geoPoint": {"lat": 36.17497, "lon": -115.13722}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Nashua", "state": "New Hampshire", "zip": "03063", "country": "United States", "geoPoint": {"lat": 42.76537, "lon": -71.46757}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Albany", "state": "New York", "zip": "12208", "country": "United States", "geoPoint": {"lat": 42.65258, "lon": -73.75623}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Durham", "state": "North Carolina", "zip": "27713", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Morehead City", "state": "North Carolina", "zip": "28557", "country": "United States", "geoPoint": {"lat": 34.72294, "lon": -76.72604}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Mentor", "state": "Ohio", "zip": "44060", "country": "United States", "geoPoint": {"lat": 41.66616, "lon": -81.33955}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Eugene", "state": "Oregon", "zip": "97401", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Portland", "state": "Oregon", "zip": "97210", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Greer", "state": "South Carolina", "zip": "29651", "country": "United States", "geoPoint": {"lat": 34.93873, "lon": -82.22706}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Myrtle Beach", "state": "South Carolina", "zip": "29572", "country": "United States", "geoPoint": {"lat": 33.68906, "lon": -78.88669}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Chattanooga", "state": "Tennessee", "zip": "37411", "country": "United States", "geoPoint": {"lat": 35.04563, "lon": -85.30968}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Austin", "state": "Texas", "zip": "78731", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Houston", "state": "Texas", "zip": "77095", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Round Rock", "state": "Texas", "zip": "78681", "country": "United States", "geoPoint": {"lat": 30.50826, "lon": -97.6789}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Ogden", "state": "Utah", "zip": "84403", "country": "United States", "geoPoint": {"lat": 41.223, "lon": -111.97383}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Federal Way", "state": "Washington", "zip": "98003", "country": "United States", "geoPoint": {"lat": 47.32232, "lon": -122.31262}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Spokane", "state": "Washington", "zip": "99202", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Tacoma", "state": "Washington", "zip": "98405", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Merewether", "state": "New South Wales", "zip": "2291", "country": "Australia", "geoPoint": {"lat": -32.94801, "lon": 151.74325}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Keswick", "state": "South Australia", "zip": "5035", "country": "Australia", "geoPoint": {"lat": -34.97487, "lon": 149.27077}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Box Hill", "state": "Victoria", "zip": "3128", "country": "Australia", "geoPoint": {"lat": -37.81887, "lon": 145.12545}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Parkville", "state": "Victoria", "zip": "3050", "country": "Australia", "geoPoint": {"lat": -37.78333, "lon": 144.95}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Brussels", "zip": "1070", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Edegem", "zip": "2650", "country": "Belgium", "geoPoint": {"lat": 51.15662, "lon": 4.44504}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Huy", "zip": "4500", "country": "Belgium", "geoPoint": {"lat": 50.51894, "lon": 5.23284}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Sint-Niklaas", "zip": "9100", "country": "Belgium", "geoPoint": {"lat": 51.16509, "lon": 4.1437}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Fortaleza", "zip": "60430-350", "country": "Brazil", "geoPoint": {"lat": -3.71722, "lon": -38.54306}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Porto Alegre", "zip": "91350250", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "S\u00e3o Paulo", "zip": "01244-030", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Edmonton", "state": "Alberta", "zip": "T5J 3N4", "country": "Canada", "geoPoint": {"lat": 53.55014, "lon": -113.46871}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Red Deer", "state": "Alberta", "zip": "T4N 6V7", "country": "Canada", "geoPoint": {"lat": 52.26682, "lon": -113.802}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Winnipeg", "state": "Manitoba", "zip": "R3E 3P4", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Halifax", "state": "Nova Scotia", "zip": "B3H 2Y9", "country": "Canada", "geoPoint": {"lat": 44.64533, "lon": -63.57239}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Oakville", "state": "Ontario", "zip": "L6H 3P1", "country": "Canada", "geoPoint": {"lat": 43.45011, "lon": -79.68292}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Laval", "state": "Quebec", "zip": "H7T 2P5", "country": "Canada", "geoPoint": {"lat": 45.56995, "lon": -73.692}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Montreal", "state": "Quebec", "zip": "H2W 1T8", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Osijek", "zip": "31000", "country": "Croatia", "geoPoint": {"lat": 45.55111, "lon": 18.69389}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Kobenhavn", "zip": "2400", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "La Rochelle", "zip": "17019", "country": "France", "geoPoint": {"lat": 46.16667, "lon": -1.15}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Le Creuzot", "zip": "71200", "country": "France"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Paris", "zip": "75022", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Rouen", "zip": "76031", "country": "France", "geoPoint": {"lat": 49.44313, "lon": 1.09932}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Athens", "zip": "10552", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Chalkida", "zip": "341 00", "country": "Greece", "geoPoint": {"lat": 38.46354, "lon": 23.60284}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Thessaloniki", "zip": "56429", "country": "Greece", "geoPoint": {"lat": 40.64361, "lon": 22.93086}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Dublin", "country": "Ireland", "geoPoint": {"lat": 53.33306, "lon": -6.24889}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Haifa", "zip": "31096", "country": "Israel", "geoPoint": {"lat": 32.81841, "lon": 34.9885}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Jerusalem", "zip": "91120", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Petah Tikva", "zip": "49100", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Petah Tiqva", "zip": "49451", "country": "Israel", "geoPoint": {"lat": 32.08707, "lon": 34.88747}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Tel Hashomer", "zip": "52621", "country": "Israel", "geoPoint": {"lat": 32.04195, "lon": 34.85623}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Jonava", "zip": "LT-55201", "country": "Lithuania", "geoPoint": {"lat": 55.08333, "lon": 24.28333}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Kaunas", "zip": "LT-51270", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Dordrecht", "zip": "3317 NM", "country": "Netherlands", "geoPoint": {"lat": 51.81, "lon": 4.67361}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Groningen", "zip": "9728 NT", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Christchurch", "zip": "8001", "country": "New Zealand", "geoPoint": {"lat": -43.53333, "lon": 172.63333}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Wellington", "zip": "6021", "country": "New Zealand", "geoPoint": {"lat": -41.28664, "lon": 174.77557}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Gdansk", "zip": "80-546", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Katowice", "zip": "40-057", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Krakow", "zip": "31-261", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Lubin", "zip": "59-300", "country": "Poland", "geoPoint": {"lat": 51.40089, "lon": 16.20149}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Lublin", "zip": "20-538", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Szczecin", "zip": "70-506", "country": "Poland", "geoPoint": {"lat": 53.42894, "lon": 14.55302}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Warsaw", "zip": "02-507", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Sturovo", "zip": "943 01", "country": "Slovakia", "geoPoint": {"lat": 47.79495, "lon": 18.7175}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Houghton", "zip": "2198", "country": "South Africa"}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Pretoria", "zip": "0002", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Somerset West", "zip": "7130", "country": "South Africa", "geoPoint": {"lat": -34.08401, "lon": 18.82113}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Alcala De Henares", "zip": "28805", "country": "Spain", "geoPoint": {"lat": 40.48205, "lon": -3.35996}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Alcira", "zip": "46600", "country": "Spain", "geoPoint": {"lat": 39.15, "lon": -0.43333}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Barcelona", "zip": "08036", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "M\u00e1laga", "zip": "29006", "country": "Spain", "geoPoint": {"lat": 36.72016, "lon": -4.42034}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Sevilla", "zip": "41014", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Seville", "zip": "41003", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Valencia", "zip": "46014", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Alings\u00e5s", "zip": "44183", "country": "Sweden", "geoPoint": {"lat": 57.93033, "lon": 12.53345}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Helsingborg", "zip": "25187", "country": "Sweden", "geoPoint": {"lat": 56.04673, "lon": 12.69437}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Huddinge", "zip": "14186", "country": "Sweden", "geoPoint": {"lat": 59.23705, "lon": 17.98192}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Karlstad", "zip": "SE-651 85", "country": "Sweden", "geoPoint": {"lat": 59.3793, "lon": 13.50357}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Bristol", "state": "Avon", "zip": "BS10 5NB", "country": "United Kingdom", "geoPoint": {"lat": 51.45523, "lon": -2.59665}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Portsmouth", "state": "Hampshire", "zip": "P06 3LY", "country": "United Kingdom", "geoPoint": {"lat": 50.79899, "lon": -1.09125}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Blackburn", "state": "Lancashire", "zip": "BB2 3HH", "country": "United Kingdom", "geoPoint": {"lat": 53.75, "lon": -2.48333}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Leicester", "state": "Leicestershire", "zip": "LE5 4PW", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Inverness", "state": "Scotland", "zip": "IV2 3JH", "country": "United Kingdom", "geoPoint": {"lat": 57.47908, "lon": -4.22398}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Ipswich", "state": "Suffolk", "zip": "IP4 5PD", "country": "United Kingdom", "geoPoint": {"lat": 52.05917, "lon": 1.15545}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Guildford", "state": "Surrey", "zip": "GU2 7XX", "country": "United Kingdom", "geoPoint": {"lat": 51.23536, "lon": -0.57427}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Swansea", "state": "Wales", "zip": "SA6 6NL", "country": "United Kingdom", "geoPoint": {"lat": 51.62079, "lon": -3.94323}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Glasgow", "zip": "G21 3UW", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Northampton", "zip": "NN1 5BD", "country": "United Kingdom", "geoPoint": {"lat": 52.25, "lon": -0.88333}}, {"facility": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "city": "Oxford", "zip": "OX3 7LJ", "country": "United Kingdom", "geoPoint": {"lat": 51.75222, "lon": -1.25596}}]}, "referencesModule": {"references": [{"pmid": "29167192", "type": "DERIVED", "citation": "Sanyal A, Cusi K, Hartman ML, Zhang S, Bastyr EJ 3rd, Bue-Valleskey JM, Chang AM, Haupt A, Jacober SJ, Konrad RJ, Zhang Q, Hoogwerf BJ. Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins. J Investig Med. 2018 Mar;66(3):661-668. doi: 10.1136/jim-2017-000609. Epub 2017 Nov 21."}, {"pmid": "28587667", "type": "DERIVED", "citation": "Orchard TJ, Cariou B, Connelly MA, Otvos JD, Zhang S, Antalis CJ, Ivanyi T, Hoogwerf BJ. The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes. Cardiovasc Diabetol. 2017 Jun 6;16(1):73. doi: 10.1186/s12933-017-0555-1."}, {"pmid": "28417532", "type": "DERIVED", "citation": "Cusi K, Sanyal AJ, Zhang S, Hartman ML, Bue-Valleskey JM, Hoogwerf BJ, Haupt A. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab. 2017 Nov;19(11):1630-1634. doi: 10.1111/dom.12973. Epub 2017 Jun 22."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "LY2605541 + Insulin Lispro", "description": "Includes participants randomized to receive LY2605541 plus Insulin Lispro.\n\nParticipant-specific dose of LY2605541 was administered subcutaneously (SC) once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "FG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Includes participants randomized to receive Insulin Glargine plus Insulin Lispro.\n\nParticipant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "664"}, {"groupId": "FG001", "numSubjects": "450"}]}, {"type": "Received at Least 1 Dose of Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "663"}, {"groupId": "FG001", "numSubjects": "449"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "548"}, {"groupId": "FG001", "numSubjects": "377"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "116"}, {"groupId": "FG001", "numSubjects": "73"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "58"}, {"groupId": "FG001", "numSubjects": "36"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "11"}]}, {"type": "Sponsor Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All participants.", "groups": [{"id": "BG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "BG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "664"}, {"groupId": "BG001", "value": "450"}, {"groupId": "BG002", "value": "1114"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "41.58", "spread": "13.50"}, {"groupId": "BG001", "value": "42.28", "spread": "13.16"}, {"groupId": "BG002", "value": "41.86", "spread": "13.36"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "267"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "436"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "397"}, {"groupId": "BG001", "value": "281"}, {"groupId": "BG002", "value": "678"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "41"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "477"}, {"groupId": "BG001", "value": "315"}, {"groupId": "BG002", "value": "792"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "164"}, {"groupId": "BG001", "value": "117"}, {"groupId": "BG002", "value": "281"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "8"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "29"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "625"}, {"groupId": "BG001", "value": "426"}, {"groupId": "BG002", "value": "1051"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "21"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "calculatePct": false, "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "343"}, {"groupId": "BG001", "value": "229"}, {"groupId": "BG002", "value": "572"}]}]}, {"title": "Slovakia", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}]}]}, {"title": "Greece", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "23"}]}]}, {"title": "Spain", "categories": [{"measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "74"}]}]}, {"title": "Ireland", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}]}, {"title": "Lithuania", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "7"}]}]}, {"title": "Israel", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "22"}]}]}, {"title": "United Kingdom", "categories": [{"measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "63"}]}]}, {"title": "France", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "19"}]}]}, {"title": "Canada", "categories": [{"measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "52"}]}]}, {"title": "Belgium", "categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "36"}]}]}, {"title": "Brazil", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "30"}]}]}, {"title": "Poland", "categories": [{"measurements": [{"groupId": "BG000", "value": "51"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "84"}]}]}, {"title": "Croatia", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}]}]}, {"title": "Denmark", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Australia", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "39"}]}]}, {"title": "South Africa", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "24"}]}]}, {"title": "Netherlands", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "New Zealand", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "14"}]}]}, {"title": "Sweden", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "26"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Hemoglobin A1c (HbA1c)", "description": "HbA1c is a test that measures a participant's average blood glucose level over a 2 to 3 month timeframe. Least squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for treatment, stratification factors (country, baseline low density lipoprotein cholesterol \\[LDL-C\\] \\[\\<100 milligrams/deciliter (mg/dL) (2.6 millimoles/liter \\[mmol/L\\]) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects and participant as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable HbA1c data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of HbA1c", "timeFrame": "52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "648"}, {"groupId": "OG001", "value": "444"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.38", "spread": "0.03"}, {"groupId": "OG001", "value": "7.61", "spread": "0.04"}]}]}]}, {"type": "SECONDARY", "title": "Hemoglobin A1c (HbA1c)", "description": "HbA1c is a test that measures a participant's average blood glucose level over the past 2 to 3 months. LS means were calculated using MMRM adjusting for treatment, stratification factors (country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects and participant as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable HbA1c data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of HbA1c", "timeFrame": "26 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "648"}, {"groupId": "OG001", "value": "444"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.09", "spread": "0.03"}, {"groupId": "OG001", "value": "7.42", "spread": "0.03"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to 52 Weeks in HbA1c", "description": "HbA1c is a test that measures a participant's average blood glucose level over a 2 to 3 month timeframe. LS means were calculated using MMRM adjusting for treatment, stratification factors (country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects and participant as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable HbA1c data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of HbA1c", "timeFrame": "Baseline, 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "648"}, {"groupId": "OG001", "value": "444"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.46", "spread": "0.03"}, {"groupId": "OG001", "value": "-0.24", "spread": "0.04"}]}]}]}, {"type": "SECONDARY", "title": "Total Hypoglycemia Events", "description": "Hypoglycemic episodes are defined as events which are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of \u226470 mg/dL (3.9 mmol/L). Group mean rates of total hypoglycemia (per 30 days) are presented and were calculated from negative binomial regression models (number of episodes = treatment + baseline total hypoglycemia rate, with log \\[exposure in days/30\\] as an offset variable). Group mean is estimated by taking the inverse link function on individual participant covariates first and then averages over all participants.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "episodes/participant/30 days", "timeFrame": "Baseline through 26 weeks, Baseline through 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "662"}, {"groupId": "OG001", "value": "449"}]}], "classes": [{"title": "Weeks 0-26", "categories": [{"measurements": [{"groupId": "OG000", "value": "16.83", "spread": "0.36"}, {"groupId": "OG001", "value": "14.66", "spread": "0.36"}]}]}, {"title": "Weeks 0-52", "categories": [{"measurements": [{"groupId": "OG000", "value": "15.34", "spread": "0.32"}, {"groupId": "OG001", "value": "13.88", "spread": "0.35"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Total Hypoglycemic Events", "description": "Hypoglycemic episodes are defined as events that are associated with the reported signs and symptoms of hypoglycemia and/or documented BG concentrations of \u226470 mg/dL (3.9 mmol/L). The percentage of participants was calculated by dividing the number of participants with hypoglycemic episodes by the total number of participants analyzed, multiplied by 100.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline through 26 weeks, Baseline through 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "662"}, {"groupId": "OG001", "value": "449"}]}], "classes": [{"title": "Weeks 0-26", "categories": [{"measurements": [{"groupId": "OG000", "value": "99.1"}, {"groupId": "OG001", "value": "99.3"}]}]}, {"title": "Weeks 0-52", "categories": [{"measurements": [{"groupId": "OG000", "value": "99.2"}, {"groupId": "OG001", "value": "99.3"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With HbA1c Equal to or Less Than 6.5% and Less Than 7.0%", "description": "The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable HbA1c data. Missing endpoints were imputed with the last observation carried forward (LOCF) method, using only post-baseline data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "up to 26 weeks, up to 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "648"}, {"groupId": "OG001", "value": "444"}]}], "classes": [{"title": "HbA1c \u22646.5%, Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.6"}, {"groupId": "OG001", "value": "17.8"}]}]}, {"title": "HbA1c \u22646.5%, Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "20.8"}, {"groupId": "OG001", "value": "15.1"}]}]}, {"title": "HbA1c <7.0%, Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "45.1"}, {"groupId": "OG001", "value": "34.5"}]}]}, {"title": "HbA1c <7.0%, Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "35.3"}, {"groupId": "OG001", "value": "26.1"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With HbA1c Less Than 7.0% and Without Nocturnal Hypoglycemia", "description": "Hypoglycemic episodes are defined as events associated with reported signs and symptoms of hypoglycemia and/or a documented blood glucose concentration of \u226470 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. The percentage of participants was calculated by dividing the number of participants with HbA1c \\<7.0% without nocturnal hypoglycemia by the total number of participants analyzed, multiplied by 100.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable data. Missing endpoints were imputed with the LOCF method, using only post-baseline data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "up to 26 weeks, up to 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "648"}, {"groupId": "OG001", "value": "444"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.1"}, {"groupId": "OG001", "value": "1.8"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.3"}, {"groupId": "OG001", "value": "1.1"}]}]}]}, {"type": "SECONDARY", "title": "Nocturnal Hypoglycemia Rates", "description": "Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or a documented BG concentration of \u226470 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. Group mean rates of nocturnal hypoglycemia (per 30 days) are presented and were calculated from negative binomial regression models (number of episodes = treatment + baseline nocturnal hypoglycemia rate, with log \\[exposure in days/30\\] as an offset variable). Group mean is estimated by taking the inverse link function on individual participant covariates first and then averages over all participants.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "events/participant/30 days", "timeFrame": "Baseline through 26 weeks, Baseline through 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "662"}, {"groupId": "OG001", "value": "449"}]}], "classes": [{"title": "Weeks 0-26", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.37", "spread": "0.07"}, {"groupId": "OG001", "value": "2.70", "spread": "0.12"}]}]}, {"title": "Weeks 0-52", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.31", "spread": "0.06"}, {"groupId": "OG001", "value": "2.46", "spread": "0.10"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Nocturnal Hypoglycemic Events", "description": "Hypoglycemic episodes are defined as events associated with the reported signs and symptoms of hypoglycemia and/or a BG concentration of \u226470 mg/dL (3.9 mmol/L). A nocturnal hypoglycemic event occurred between bedtime and waking and between the time points of 10:00 PM and 10:00 AM. The percentage of participants was calculated by dividing the number of participants with nocturnal hypoglycemic episodes by the total number of participants analyzed, multiplied by 100.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline through 26 weeks, Baseline through 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "662"}, {"groupId": "OG001", "value": "449"}]}], "classes": [{"title": "Weeks 0-26", "categories": [{"measurements": [{"groupId": "OG000", "value": "81.7"}, {"groupId": "OG001", "value": "94.7"}]}]}, {"title": "Weeks 0-52", "categories": [{"measurements": [{"groupId": "OG000", "value": "87.5"}, {"groupId": "OG001", "value": "96.2"}]}]}]}, {"type": "SECONDARY", "title": "Change in Body Weight", "description": "LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline body weight as fixed effects and participant as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable body weight data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kilograms (kg)", "timeFrame": "Baseline, 26 weeks, 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "648"}, {"groupId": "OG001", "value": "439"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.55", "spread": "0.14"}, {"groupId": "OG001", "value": "0.78", "spread": "0.16"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.61", "spread": "0.17"}, {"groupId": "OG001", "value": "1.21", "spread": "0.20"}]}]}]}, {"type": "SECONDARY", "title": "9 Point Self-monitored Blood Glucose (SMBG)", "description": "9-point SMBG profiles were obtained over 2 days within the week prior to Weeks 0, 4, 12, 26, 39, and 52. SMBG measurements were taken at 9 time points: pre-morning meal, 2 hours post-morning meal, pre-midday meal, 2 hours post-midday meal, pre-evening meal, 2 hours post-evening meal, bedtime, at approximately 0300 hours, and the subsequent morning prior to the morning meal. LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline BG values as the fixed effects and participant as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable SMBG data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "26 weeks and 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "416"}]}], "classes": [{"title": "Pre-morning meal, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "416"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "153.85", "spread": "2.67"}, {"groupId": "OG001", "value": "148.91", "spread": "3.17"}]}]}, {"title": "Pre-morning meal, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "615"}, {"groupId": "OG001", "value": "416"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "156.18", "spread": "2.75"}, {"groupId": "OG001", "value": "155.25", "spread": "3.30"}]}]}, {"title": "2 hour post-morning meal, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "572"}, {"groupId": "OG001", "value": "380"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "164.59", "spread": "3.44"}, {"groupId": "OG001", "value": "178.47", "spread": "4.07"}]}]}, {"title": "2 hour post-morning meal, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "572"}, {"groupId": "OG001", "value": "380"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "171.94", "spread": "3.43"}, {"groupId": "OG001", "value": "183.35", "spread": "4.10"}]}]}, {"title": "Pre-midday meal, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "611"}, {"groupId": "OG001", "value": "403"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "136.70", "spread": "2.70"}, {"groupId": "OG001", "value": "152.87", "spread": "3.22"}]}]}, {"title": "Pre-midday meal, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "611"}, {"groupId": "OG001", "value": "403"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "145.22", "spread": "2.87"}, {"groupId": "OG001", "value": "158.50", "spread": "3.42"}]}]}, {"title": "2 hour post-midday meal, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "579"}, {"groupId": "OG001", "value": "379"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "150.66", "spread": "3.32"}, {"groupId": "OG001", "value": "164.47", "spread": "3.94"}]}]}, {"title": "2 hour post-midday meal, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "579"}, {"groupId": "OG001", "value": "379"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "156.92", "spread": "3.73"}, {"groupId": "OG001", "value": "172.61", "spread": "4.42"}]}]}, {"title": "Pre-evening meal, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "603"}, {"groupId": "OG001", "value": "407"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "155.38", "spread": "3.13"}, {"groupId": "OG001", "value": "176.50", "spread": "3.73"}]}]}, {"title": "Pre-evening meal, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "603"}, {"groupId": "OG001", "value": "407"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "153.30", "spread": "3.21"}, {"groupId": "OG001", "value": "170.83", "spread": "3.79"}]}]}, {"title": "2 hour post-evening meal, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "559"}, {"groupId": "OG001", "value": "373"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "160.50", "spread": "3.85"}, {"groupId": "OG001", "value": "181.18", "spread": "4.54"}]}]}, {"title": "2 hour post-evening meal, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "559"}, {"groupId": "OG001", "value": "373"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "169.61", "spread": "4.19"}, {"groupId": "OG001", "value": "184.19", "spread": "4.99"}]}]}, {"title": "Bedtime, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "578"}, {"groupId": "OG001", "value": "382"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "163.90", "spread": "3.24"}, {"groupId": "OG001", "value": "180.97", "spread": "3.84"}]}]}, {"title": "Bedtime, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "578"}, {"groupId": "OG001", "value": "382"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "168.04", "spread": "3.58"}, {"groupId": "OG001", "value": "187.09", "spread": "4.30"}]}]}, {"title": "0300 Hours, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "529"}, {"groupId": "OG001", "value": "347"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "169.64", "spread": "3.69"}, {"groupId": "OG001", "value": "163.09", "spread": "4.39"}]}]}, {"title": "0300 Hours, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "529"}, {"groupId": "OG001", "value": "347"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "168.72", "spread": "3.94"}, {"groupId": "OG001", "value": "174.11", "spread": "4.72"}]}]}, {"title": "Pre-morning meal next day, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "583"}, {"groupId": "OG001", "value": "403"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "150.04", "spread": "2.76"}, {"groupId": "OG001", "value": "145.77", "spread": "3.23"}]}]}, {"title": "Pre-morning meal next day, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "583"}, {"groupId": "OG001", "value": "403"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "151.22", "spread": "2.70"}, {"groupId": "OG001", "value": "149.56", "spread": "3.20"}]}]}]}, {"type": "SECONDARY", "title": "Fasting Serum Glucose (by Laboratory Measurement)", "description": "Fasting serum glucose (FSG) is measured in blood before the morning meal. LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline HbA1c as the fixed effects and participant as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable FSG data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "26 weeks and 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "646"}, {"groupId": "OG001", "value": "443"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "139.76", "spread": "2.75"}, {"groupId": "OG001", "value": "155.23", "spread": "3.25"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "142.02", "spread": "2.95"}, {"groupId": "OG001", "value": "171.67", "spread": "3.48"}]}]}]}, {"type": "SECONDARY", "title": "Fasting Blood Glucose (by Participant Self Monitored Blood Glucose Readings)", "description": "Fasting blood glucose (FBG) was measured by SMBG pre-morning meal. LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline FBG as the fixed effects and participant as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable FBG data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "26 weeks and 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "643"}, {"groupId": "OG001", "value": "441"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "154.84", "spread": "1.96"}, {"groupId": "OG001", "value": "151.46", "spread": "2.31"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "159.85", "spread": "2.02"}, {"groupId": "OG001", "value": "153.09", "spread": "2.39"}]}]}]}, {"type": "SECONDARY", "title": "Intra-participant Variability of Fasting Blood Glucose (FBG)", "description": "FBG was measured by SMBG. Between-day glucose variability is measured by the standard deviation (SD) of FBG. LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline SD of FBG as the fixed effects and participant as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable FBG data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "26 weeks and 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "639"}, {"groupId": "OG001", "value": "437"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "51.70", "spread": "1.22"}, {"groupId": "OG001", "value": "64.73", "spread": "1.44"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "53.97", "spread": "1.24"}, {"groupId": "OG001", "value": "63.11", "spread": "1.46"}]}]}]}, {"type": "SECONDARY", "title": "0300 Hours Blood Glucose (BG) to Fasting BG Excursion", "description": "Results of a 0300-hour to pre-morning meal (FBG) excursion are presented (only excursions within a single SMBG profile are included). LS means were calculated using MMRM adjusting for treatment, stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], baseline prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment-by-visit interaction, and baseline excursion as the fixed effects and participant as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable SMBG data at baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "26 weeks and 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "498"}, {"groupId": "OG001", "value": "332"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "-25.49", "spread": "3.96"}, {"groupId": "OG001", "value": "-16.44", "spread": "4.72"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "-23.36", "spread": "4.10"}, {"groupId": "OG001", "value": "-29.01", "spread": "4.87"}]}]}]}, {"type": "SECONDARY", "title": "Triglycerides, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C), and Total Cholesterol", "description": "Concentrations of cholesterol, HDL-C, and LDL-C, and triglycerides are presented. LS means were calculated using MMRM adjusting for stratification factors (baseline HbA1c \\[\u22648.5% and \\>8.5%\\], country, LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L), except for the LDL-C outcome variable\\], prior basal insulin therapy \\[insulin glargine/detemir/other\\]), visit, treatment, treatment-by-visit interaction, and baseline value of corresponding lipid outcome variable as the fixed effects and participant as a random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable lipid data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "26 weeks and 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "650"}, {"groupId": "OG001", "value": "446"}]}], "classes": [{"title": "Cholesterol, Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "185.51", "spread": "1.09"}, {"groupId": "OG001", "value": "179.30", "spread": "1.29"}]}]}, {"title": "Cholesterol, Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "184.66", "spread": "1.13"}, {"groupId": "OG001", "value": "178.13", "spread": "1.34"}]}]}, {"title": "HDL-C, Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "58.44", "spread": "0.39"}, {"groupId": "OG001", "value": "61.52", "spread": "0.46"}]}]}, {"title": "HDL-C, Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "58.13", "spread": "0.39"}, {"groupId": "OG001", "value": "59.52", "spread": "0.46"}]}]}, {"title": "LDL-C, Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "106.25", "spread": "0.90"}, {"groupId": "OG001", "value": "100.90", "spread": "1.07"}]}]}, {"title": "LDL-C, Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "105.80", "spread": "0.96"}, {"groupId": "OG001", "value": "101.20", "spread": "1.14"}]}]}, {"title": "Triglycerides, Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "105.26", "spread": "2.30"}, {"groupId": "OG001", "value": "85.11", "spread": "2.73"}]}]}, {"title": "Triglycerides, Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "104.84", "spread": "2.17"}, {"groupId": "OG001", "value": "88.12", "spread": "2.57"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Change in Anti-LY2605541 Antibodies", "description": "The percentage of participants with anti-LY2605541 treatment-emergent antibody response (TEAR) is summarized. TEAR is defined as change from baseline to post-baseline in the anti-LY2605541 antibody level either from undetectable to detectable, or from detectable to the value with at least 130% relative increase from baseline.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable anti-LY2605541 antibody data at baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "26 weeks, 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "556"}, {"groupId": "OG001", "value": "399"}]}], "classes": [{"title": "Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "556"}, {"groupId": "OG001", "value": "399"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "30.2"}, {"groupId": "OG001", "value": "14.0"}]}]}, {"title": "Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "509"}, {"groupId": "OG001", "value": "363"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "32.8"}, {"groupId": "OG001", "value": "10.2"}]}]}]}, {"type": "SECONDARY", "title": "Basal, Meal Time, and Total Insulin Dose Per Body Weight", "description": "Basal insulin dose, meal-time insulin dose (short-acting bolus dose), and total insulin dose were calculated based on the dose during the last 7 days prior to the post-treatment visit or last 3 days prior to the randomization visit. LS means were calculated using a constrained Longitudinal Data Analysis (cLDA) model adjusting for indicator variables of each treatment group at each postbaseline visit and stratification variables (baseline HbA1c \\[\u22648.5% and\\> 8.5%\\], country, baseline LDL-C \\[\\<100 mg/dL (2.6 mmol/L) and \u2265100 mg/dL (2.6 mmol/L)\\], and baseline prior basal insulin therapy \\[insulin glargine/detemir/ other\\]) as fixed effects.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable insulin dose data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units/weight/day", "timeFrame": "26 weeks and 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "551"}, {"groupId": "OG001", "value": "392"}]}], "classes": [{"title": "Basal insulin, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "527"}, {"groupId": "OG001", "value": "374"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.46", "spread": "0.01"}, {"groupId": "OG001", "value": "0.35", "spread": "0.01"}]}]}, {"title": "Basal insulin, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "508"}, {"groupId": "OG001", "value": "367"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.47", "spread": "0.01"}, {"groupId": "OG001", "value": "0.35", "spread": "0.01"}]}]}, {"title": "Meal time insulin, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "542"}, {"groupId": "OG001", "value": "388"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.32", "spread": "0.01"}, {"groupId": "OG001", "value": "0.44", "spread": "0.01"}]}]}, {"title": "Meal time insulin, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "490"}, {"groupId": "OG001", "value": "352"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.33", "spread": "0.01"}, {"groupId": "OG001", "value": "0.43", "spread": "0.01"}]}]}, {"title": "Total insulin, Week 26", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "551"}, {"groupId": "OG001", "value": "392"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.75", "spread": "0.01"}, {"groupId": "OG001", "value": "0.77", "spread": "0.01"}]}]}, {"title": "Total insulin, Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "509"}, {"groupId": "OG001", "value": "369"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.78", "spread": "0.01"}, {"groupId": "OG001", "value": "0.77", "spread": "0.02"}]}]}]}, {"type": "SECONDARY", "title": "Insulin Treatment Satisfaction Questionnaire", "description": "Insulin Treatment Satisfaction Questionnaire (ITSQ) is a validated measure containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. The questionnaire measures satisfaction from the following 5 domains: Convenience of Regimen, Lifestyle Flexibility, Glycemic Control, Hypoglycemic Control, and Insulin Delivery Device. Data are transformed to a scale of 0-100, where higher scores indicate better treatment satisfaction. LS means were calculated using an ANCOVA model adjusting for treatment, baseline HbA1c (\u22648.5% and \\>8.5%), country, and baseline prior basal insulin therapy (insulin glargine/detemir/other) as fixed effects and baseline ITSQ scores as a covariate.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable ITSQ data at both baseline and post-baseline. Missing endpoints were imputed with the LOCF method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "up to 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "561"}, {"groupId": "OG001", "value": "406"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "73.60", "spread": "0.57"}, {"groupId": "OG001", "value": "72.92", "spread": "0.67"}]}]}]}, {"type": "SECONDARY", "title": "European Quality of Life -5 Dimension (EQ-5D-3L)", "description": "The EQ-5D-3L is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a three-level scale of 1-3 (no problem, some problems, and extreme problems). These combinations of attributes are converted into a weighted health-state Index Score according to the United States population-based algorithm. Scores range from -0.11 to 1.0, where a score of 1.0 indicates perfect health. LS means were calculated using an ANCOVA adjusting for treatment, baseline HbA1c (\u22648.5% and \\>8.5%), country, baseline prior basal insulin therapy (insulin glargine/detemir/other), and baseline EQ-5D-3L score as covariates.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable EQ-5D-3L data at both baseline and post-baseline. Missing endpoints were imputed with the LOCF method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "up to 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "566"}, {"groupId": "OG001", "value": "406"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.91", "spread": "0.00"}, {"groupId": "OG001", "value": "0.92", "spread": "0.01"}]}]}]}, {"type": "SECONDARY", "title": "Adult Low Blood Sugar Survey", "description": "Low Blood Sugar Survey (LBSS) (also referenced as Hypoglycemia Fear Survey - II \\[HFS-II\\]) is a questionnaire that measures 1) behaviors to avoid hypoglycemia and its negative consequences (15 items) and 2) worries about hypoglycemia and its negative consequences (18 items). Responses are made on a 5-point Likert-type scale where 0 = Never and 4 = Always. Total score is the sum of all items (range 0-132). Higher total scores reflect greater fear of hypoglycemia. LS means were calculated using MMRM adjusting for treatment, baseline HbA1c (\u22648.5% and \\>8.5%), country, baseline prior basal insulin therapy (insulin glargine/detemir/other), visit, treatment-by-visit interaction, and baseline LBSS score as the fixed effects and participant as the random effect.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable LBSS data at both baseline and post-baseline.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "26 weeks and 52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "657"}, {"groupId": "OG001", "value": "447"}]}], "classes": [{"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.48", "spread": "0.55"}, {"groupId": "OG001", "value": "29.12", "spread": "0.65"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.43", "spread": "0.59"}, {"groupId": "OG001", "value": "29.27", "spread": "0.70"}]}]}]}, {"type": "SECONDARY", "title": "Rapid Assessment of Physical Activity (RAPA)", "description": "The RAPA questionnaire assesses the level and intensity of physical activity of adult participants. It contains 2 subscales: RAPA 1 (Aerobic) and RAPA 2 (Strength and Flexibility). RAPA 1 contains 7 questions regarding the participant's amount and intensity of physical activity, allowing each participant's aerobic activity level to be categorized as sedentary, underactive, light activity, regular underactive, or active. RAPA 2 contains 2 questions regarding participants' physical activities that increase strength and improve flexibility. Each participant's strength and flexibility activity level is then categorized as neither strength nor flexibility activity, either strength or flexibility activity (not both), both strength and flexibility activity. The percentage of participants in each RAPA 1/2 category is presented and was calculated by dividing the number of participants in each RAPA 1/2 category by the total number of participants analyzed, multiplied by 100.", "populationDescription": "Participants who were randomized, had at least 1 dose of study medication, and had evaluable RAPA data.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "52 weeks", "groups": [{"id": "OG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}, {"id": "OG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "367"}, {"groupId": "OG001", "value": "254"}]}], "classes": [{"title": "RAPA 1, Sedentary", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "364"}, {"groupId": "OG001", "value": "249"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.1"}, {"groupId": "OG001", "value": "1.2"}]}]}, {"title": "RAPA 1, Underactive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "364"}, {"groupId": "OG001", "value": "249"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8"}, {"groupId": "OG001", "value": "4.8"}]}]}, {"title": "RAPA 1, Light activity", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "364"}, {"groupId": "OG001", "value": "249"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13.7"}, {"groupId": "OG001", "value": "14.5"}]}]}, {"title": "RAPA 1, Regular underactive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "364"}, {"groupId": "OG001", "value": "249"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "24.5"}, {"groupId": "OG001", "value": "28.5"}]}]}, {"title": "RAPA 1, Active", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "364"}, {"groupId": "OG001", "value": "249"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "56.9"}, {"groupId": "OG001", "value": "51.0"}]}]}, {"title": "RAPA 2, Neither strength/flexibility", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "367"}, {"groupId": "OG001", "value": "254"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "39.0"}, {"groupId": "OG001", "value": "46.9"}]}]}, {"title": "RAPA 2, Either strength/flexibility", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "367"}, {"groupId": "OG001", "value": "254"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "28.9"}, {"groupId": "OG001", "value": "26.8"}]}]}, {"title": "RAPA 2, Both strength/flexibility", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "367"}, {"groupId": "OG001", "value": "254"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "32.2"}, {"groupId": "OG001", "value": "26.4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "eventGroups": [{"id": "EG000", "title": "LY2605541 + Insulin Lispro", "description": "Participant-specific dose of LY2605541 was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks.", "seriousNumAffected": 117, "seriousNumAtRisk": 663, "otherNumAffected": 502, "otherNumAtRisk": 663}, {"id": "EG001", "title": "Insulin Glargine + Insulin Lispro", "description": "Participant-specific dose of Insulin Glargine was administered SC once daily at bedtime for 52 weeks.\n\nParticipant-specific dose of Insulin Lispro was administered SC at meal times for 52 weeks.", "seriousNumAffected": 92, "seriousNumAtRisk": 449, "otherNumAffected": 305, "otherNumAtRisk": 449}], "seriousEvents": [{"term": "Autoimmune thrombocytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Lymphadenopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 449}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 449}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Arteriosclerosis coronary artery", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Coronary artery occlusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Colitis microscopic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Enteritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Drug-induced liver injury", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Drug hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Food allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Abscess limb", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Abscess oral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Gastritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Lobar pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Osteomyelitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Viraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Accident at home", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Eye injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Gun shot wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Hand fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Intentional overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Radius fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Thermal burn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 449}]}, {"term": "Upper limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Wrist fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Hepatic enzyme increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Liver function test abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Weight decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 449}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 449}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 108, "numAffected": 71, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 95, "numAffected": 58, "numAtRisk": 449}]}, {"term": "Ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Lumbar spinal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Neuropathic arthropathy", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Adenocarcinoma gastric", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Benign hydatidiform mole", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Bladder papilloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Cerebellopontine angle tumour", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Intraductal proliferative breast lesion", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Non-small cell lung cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Oesophageal carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Squamous cell carcinoma of the tongue", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 169}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Encephalopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Hypoglycaemic seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Hypoglycaemic unconsciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Transient global amnesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Hyperemesis gravidarum", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 169}]}, {"term": "Pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 267}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 169}]}, {"term": "Acute psychosis", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Major depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Nephrotic syndrome", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 267}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 169}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Respiratory distress", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Lipohypertrophy", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 2, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Skin ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Haemorrhage", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Peripheral ischaemia", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 14, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 17, "numAffected": 16, "numAtRisk": 449}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 27, "numAffected": 21, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 18, "numAffected": 17, "numAtRisk": 449}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 20, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 21, "numAffected": 16, "numAtRisk": 449}]}, {"term": "Injection site hypertrophy", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 16, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 449}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 16, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 14, "numAffected": 12, "numAtRisk": 449}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 12, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 14, "numAffected": 11, "numAtRisk": 449}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 18, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 15, "numAffected": 15, "numAtRisk": 449}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 47, "numAffected": 45, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 23, "numAffected": 22, "numAtRisk": 449}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 141, "numAffected": 105, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 99, "numAffected": 70, "numAtRisk": 449}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 33, "numAffected": 29, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 19, "numAffected": 14, "numAtRisk": 449}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 76, "numAffected": 61, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 52, "numAffected": 40, "numAtRisk": 449}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 28, "numAffected": 24, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 18, "numAffected": 15, "numAtRisk": 449}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 7, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 12, "numAffected": 12, "numAtRisk": 449}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 17, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 449}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 15, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 449}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 14, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 12, "numAffected": 10, "numAtRisk": 449}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 37, "numAffected": 24, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 21, "numAffected": 14, "numAtRisk": 449}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 32, "numAffected": 31, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 15, "numAffected": 14, "numAtRisk": 449}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 14, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 12, "numAffected": 12, "numAtRisk": 449}]}, {"term": "Lipohypertrophy", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 69, "numAffected": 55, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 449}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 16.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 11, "numAtRisk": 663}, {"groupId": "EG001", "numEvents": 11, "numAffected": 11, "numAtRisk": 449}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Chief Medical Officer", "organization": "Eli Lilly and Company", "phone": "800-545-5979"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Slovenia", "Turkey"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003922", "term": "Diabetes Mellitus, Type 1"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}, {"id": "D000001327", "term": "Autoimmune Diseases"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7117", "name": "Diabetes Mellitus, Type 1", "asFound": "Diabetes Mellitus, Type 1", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}, {"id": "M4629", "name": "Autoimmune Diseases", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000061268", "term": "Insulin Lispro"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M29802", "name": "Insulin Lispro", "asFound": "AUC", "relevance": "HIGH"}, {"id": "M347", "name": "Insulin Glargine", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}